• Molecular NameSpectinomycin
  • SynonymActinospectacina [Italian]; Antibiotic 2233wp; Espectinomicina [INN-Spanish]; SCM; Spectinomicina [Italian]; Spectinomycin Di HCl; Spectinomycin HCl/ Sulphate; Spectinomycine [INN-French]; Spectinomycinum [INN-Latin]
  • Weight332.353
  • Drugbank_IDDB00919
  • ACS_NO1695-77-8
  • Show 2D model
  • LogP (experiment)-2.88
  • LogP (predicted, AB/LogP v2.0)-2.75
  • pka6.95
  • LogD (pH=7, predicted)-4.5
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.31
  • LogSw (predicted, AB/LogsW2.0)1893.8
  • Sw (mg/ml) (predicted, ACD/Labs)0.25
  • No.of HBond Donors5
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds2
  • TPSA129.51
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn aminocyclitol antibiotic, closely related to the aminoglycosides, produced by the bacterium Streptomyces spectabilis.
  • Absorption_valueN/A
  • Absorption (description)Rapidly and almost completely absorbed after intramuscular injection.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding10.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life1~3 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAcute oral toxicity (LD50): [Rat]. Information on overdosage in humans is not available.
  • LD50 (rat)LD50>5000 mg/kg
  • LD50 (mouse)N/A